Compare OLN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLN | ARQT |
|---|---|---|
| Founded | 1892 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 1994 | 2020 |
| Metric | OLN | ARQT |
|---|---|---|
| Price | $25.04 | $24.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $25.23 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,780,800,000.00 | $376,072,000.00 |
| Revenue This Year | $2.57 | $34.85 |
| Revenue Next Year | $3.51 | $29.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.68 | ★ 91.34 |
| 52 Week Low | $18.08 | $13.06 |
| 52 Week High | $30.46 | $31.77 |
| Indicator | OLN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 66.61 |
| Support Level | $22.82 | $22.41 |
| Resistance Level | $26.84 | $25.25 |
| Average True Range (ATR) | 0.85 | 0.94 |
| MACD | -0.09 | 0.48 |
| Stochastic Oscillator | 41.51 | 85.49 |
Olin Corp manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on the product type. The Chlor alkali products and Vinyls segment, which generates the majority of revenue, sells chlorine and caustic soda, which are used in a variety of industries including cosmetics, textiles, crop protection, and fire protection products. The Epoxy segment sells epoxy resins used in paints and coatings. The Winchester segment sells sporting ammunition and ammunition accessories under the Winchester brand. The majority of revenue comes from the United States.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.